Search

Your search keyword '"Pol, Jonathan G."' showing total 173 results

Search Constraints

Start Over You searched for: Author "Pol, Jonathan G." Remove constraint Author: "Pol, Jonathan G."
173 results on '"Pol, Jonathan G."'

Search Results

1. Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma

6. Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis

7. Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses

9. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

10. Autophagy-mediated metabolic effects of aspirin

13. Table S4 from A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency

15. Supplementary Figures and Tables from A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency

16. Data from A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency

19. Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy

26. S6K-STING interaction regulates cytosolic DNA–mediated activation of the transcription factor IRF3

30. A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency

33. Dynamical Boolean Modeling of Immunogenic Cell Death

34. The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome

35. Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

37. The Abundance of Long Intergenic Non-coding RNA 01087 Differentiates Luminal From Triple-negative Breast Cancer Patients and Predicts Their Clinical Outcome

41. Trial watch: dietary interventions for cancer therapy

42. A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice

43. Repurposing CD8+ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?

44. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

45. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

50. Alternative splicing‐regulated protein of hepatitis B virus hacks the TNF‐α‐stimulated signaling pathways and limits the extent of liver inflammation

Catalog

Books, media, physical & digital resources